These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

1015 related items for PubMed ID: 11726894

  • 1. Perioperative use of tirofiban hydrochloride (Aggrastat) does not increase surgical bleeding after emergency or urgent coronary artery bypass grafting.
    Bizzarri F, Scolletta S, Tucci E, Lucidi M, Davoli G, Toscano T, Neri E, Muzzi L, Frati G.
    J Thorac Cardiovasc Surg; 2001 Dec; 122(6):1181-5. PubMed ID: 11726894
    [Abstract] [Full Text] [Related]

  • 2. Safety and efficacy of thrombolysis with alteplase (50 mg) plus tirofiban versus alteplase (100 mg) alone in acute myocardial infarction: preliminary findings.
    Sarullo FM, Pasquale PD, D'Alfonso G, Amerigo L, Cannizzaro S, Castello A.
    Ital Heart J; 2001 Aug; 2(8):605-11. PubMed ID: 11577835
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Safety of glycoprotein IIb/IIIa inhibitors in urgent or emergency coronary artery bypass graft surgery.
    Cheng DK, Jackevicius CA, Seidelin P, Feindel C, Rouleau JL.
    Can J Cardiol; 2004 Feb; 20(2):223-8. PubMed ID: 15010747
    [Abstract] [Full Text] [Related]

  • 9. Platelet inhibition by increased tirofiban dosing during primary coronary angioplasty for ST elevation myocardial infarction.
    Kralisz P, Dobrzycki S, Nowak K, Kochman W, Gajewska-Bachórzewska H, Gugała K, Mezyński G, Prokopczuk P, Zuk J, Korecki J, Poniatowski B, Musiał W.
    Kardiol Pol; 2004 May; 60(5):459-67. PubMed ID: 15247961
    [Abstract] [Full Text] [Related]

  • 10. Analysis of bleeding complications associated with glycoprotein IIb/IIIa receptors blockade in patients with high-risk acute coronary syndromes: insights from the PRISM-PLUS study.
    Huynh T, Piazza N, DiBattiste PM, Snapinn SM, Wan Y, Pharand C, Theroux P.
    Int J Cardiol; 2005 Apr 08; 100(1):73-8. PubMed ID: 15820288
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Perioperative monitoring of primary and secondary hemostasis in coronary artery bypass grafting.
    Hertfelder HJ, Bös M, Weber D, Winkler K, Hanfland P, Preusse CJ.
    Semin Thromb Hemost; 2005 Apr 08; 31(4):426-40. PubMed ID: 16149021
    [Abstract] [Full Text] [Related]

  • 14. Patients with non-ST-elevation acute coronary syndromes undergoing coronary artery bypass grafting in the modern era of antithrombotic therapy.
    Chew DP, Huang Z, Pieper KS, White H, Mahaffey KW, Ferguson JJ, Califf RM, Aylward PG.
    Am Heart J; 2008 Feb 08; 155(2):239-44. PubMed ID: 18215592
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Aprotinin decreases postoperative bleeding and number of transfusions in patients on clopidogrel undergoing coronary artery bypass graft surgery: a double-blind, placebo-controlled, randomized clinical trial.
    van der Linden J, Lindvall G, Sartipy U.
    Circulation; 2005 Aug 30; 112(9 Suppl):I276-80. PubMed ID: 16159831
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Effects of preoperative aspirin and clopidogrel therapy on perioperative blood loss and blood transfusion requirements in patients undergoing off-pump coronary artery bypass graft surgery.
    Shim JK, Choi YS, Oh YJ, Bang SO, Yoo KJ, Kwak YL.
    J Thorac Cardiovasc Surg; 2007 Jul 30; 134(1):59-64. PubMed ID: 17599487
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Promise of combined low-molecular-weight heparin and platelet glycoprotein IIb/IIIa inhibition: results from Platelet IIb/IIIa Antagonist for the Reduction of Acute coronary syndrome events in a Global Organization Network B (PARAGON B).
    Mukherjee D, Mahaffey KW, Moliterno DJ, Harrington RA, Yadav JS, Pieper KS, Gallup D, Dyke C, Roe MT, Berdan L, Lauer MS, Mänttäri M, White HD, Califf RM, Topol EJ.
    Am Heart J; 2002 Dec 30; 144(6):995-1002. PubMed ID: 12486423
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 51.